Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Melanoma 3Squamous Cell Carcinoma of Head and Neck 2Sezary Syndrome 2Sarcoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Leukemia 2Carcinoma, Renal Cell 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Skin Neoplasms 1Recurrence 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Liver Neoplasms 1Leukemia-Lymphoma, Adult T-Cell 1

Interventions

mogamulizumab 4Lenalidomide 4Cyclophosphamide 3Gemcitabine 2Doxorubicin 2Alemtuzumab 2ruxolitinib 1peginterferon alfa-2b 1liposomal doxorubicin 1fludarabine phosphate 1fludarabine 1etoposide phosphate 1dolutegravir 1denileukin diftitox 1cobomarsen 1brincidofovir 1belinostat 1Zidovudine 1Vincristine 1Tenofovir 1Taxes 1Raltegravir Potassium 1Prednisone 1Panobinostat 1Paclitaxel 1Oxaliplatin 1Lomustine 1Irinotecan 1Introns 1Interleukin-15 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia-Lymphoma, Adult T-Cell × Interleukin-15 × Clear all
NCT02689453 2022-04-29

Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
11 enrolled 16 charts
DermatologicLymphoidOther hematologic neoplasm

Leukemia-Lymphoma, Adult T-Cell, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡